Research
HC Wainwright Initiates Relmada Therapeutics at Buy With $12 Price Target
Relmada Therapeutics (RLMD) has an average rating of buy and mean price target of $12.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$RLMD
